AKT1 and Parkinson disease: Moreover, activation of Shh signaling by purmorphamine inhibited activation of lipopolysaccharide-treated BV2 microglia through the PI3K/AKT pathway and protected dopaminergic neurons in a mouse model of Parkinson’s disease [43].